Treatment of endometriosis with goserelin depot, a long-acting gonadotropin-releasing hormone agonist analog: endocrine and clinical results

Fertil Steril. 1990 Dec;54(6):1021-7. doi: 10.1016/s0015-0282(16)53999-5.

Abstract

Thirty-two patients with laparoscopic diagnosis of endometriosis were treated for 6 months with the gonadotropin-releasing hormone agonist goserelin depot. Hormonal and clinical evaluations were conducted during treatment and for a 6-month follow-up period. Serum 17 beta-estradiol levels were sharply suppressed. Luteinizing hormone was also decreased, whereas follicle-stimulating hormone, after an initial fall, gradually rose to pretreatment levels. Ovarian androgenic production was less inhibited, total testosterone being the only significantly suppressed hormone. There was a marked improvement of signs and symptoms of endometriosis and a 47.3% reduction of laparoscopic score. The results of this study suggest that goserelin depot provides a very good suppression of ovarian estrogen production and is highly effective in decreasing the symptoms of endometriosis with an acceptable compliance by the patient.

MeSH terms

  • Adult
  • Buserelin / analogs & derivatives*
  • Buserelin / therapeutic use
  • Delayed-Action Preparations
  • Endocrine Glands / drug effects*
  • Endometriosis / blood
  • Endometriosis / drug therapy*
  • Endometriosis / physiopathology
  • Female
  • Gonadal Steroid Hormones / blood
  • Gonadotropin-Releasing Hormone / physiology*
  • Goserelin
  • Humans
  • Menstrual Cycle / drug effects
  • Prolactin / blood

Substances

  • Delayed-Action Preparations
  • Gonadal Steroid Hormones
  • Goserelin
  • Gonadotropin-Releasing Hormone
  • Prolactin
  • Buserelin